Skip to main content
Skip to main content
JDHIF logo

JD Health International Inc. (JDHIF)

$5.85 +$0.00 (+0.00%) |CouncilBUY · 58 · B
Bottom line: BUY — our Council read (58/100) and AI Score (51/100) broadly agree. Strongest single signal: Seth Klarman bullish.
MCap: $18.66B| Vol: 200| 52-wk range: $3.23 – $8.75
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

JD Health International Inc. (JDHIF) trades at $5.85 with AI Score 51/100 (Grade B). JD Health International Inc. Market cap: $18.66B, Sector: Healthcare.

Price live · AI analysis from Jun 14, 2026
JD Health International Inc. operates a comprehensive online healthcare platform in China, offering a wide range of pharmaceutical and healthcare products along with various online services. Founded in 2018, the company has rapidly established itself as a key player in the healthcare sector.

Analyst Coverage for JDHIF: JDHIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates JDHIF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.

Council Score · Weighted Average of 3 Disciplines
BUY 58/100 · B

JDHIF: 5/6 perspectives are bullish. Dominant signal: Seth Klarman bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Jim Simons
Bullish
Izzy Englander
Bullish
Seth Klarman
Bullish
Moon AI
Bullish
Council Score · 8 perspectives · See tabs for details →

JD Health International Inc. (JDHIF) Healthcare & Pipeline Overview

CEOCao Dong
Employees3564
HeadquartersBeijing, CN
IPO Year2020

JD Health International Inc. stands out in the healthcare sector with its extensive online platform that delivers pharmaceutical products and healthcare services, catering to the growing demand for digital health solutions in China.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Jun 14, 2026

What Is the Investment Thesis for JDHIF?

JD Health International Inc. presents a compelling investment thesis driven by its strong market position and growth potential in China's healthcare sector. With a market capitalization of $18.66B and a P/E ratio of 19.47, the company demonstrates solid profitability, evidenced by a profit margin of 7.3% and a gross margin of 24.8%. The ongoing digital transformation in healthcare, coupled with increasing consumer demand for online medical services, provides a robust growth trajectory. Key value drivers include the expansion of its online pharmacy network and the introduction of innovative healthcare solutions. The company's ability to scale its operations and enhance service offerings will be critical as it navigates the competitive landscape, particularly against established players like Bayer AG (BAYRY) and Fresenius SE & Co. KGaA (FSNUF). However, potential regulatory changes and market volatility present risks that investors may want to evaluate.

Based on FMP financials and quantitative analysis

JDHIF Key Highlights

  • Market capitalization of $18.66B reflects strong investor confidence in the company's growth prospects.
  • P/E ratio of 19.47 indicates a reasonable valuation relative to its earnings potential.
  • Profit margin of 7.3% and gross margin of 24.8% highlight operational efficiency and profitability.
  • Employee base of 3,564 supports the company's extensive service offerings and operational capabilities.
  • No dividend yield currently, indicating a focus on reinvestment for growth.

Who Are JDHIF's Competitors?

JDHIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
BAYRY Bayer AG $14.56 -4.11% $57.24B 51
SDZNY Sandoz Group AG $87.73 -2.01% $37.96B 51
OTSKY Otsuka Holdings Co., Ltd. $36.05 -0.21% $38.01B 58
FSNUF Fresenius SE & Co. KGaA $57.00 +4.88% $32.10B 44
RYLPF Koninklijke Philips N.V. $25.99 -5.16% $25.24B 44
HWAIF Healwell AI Inc. $0.53 -3.52% $160.75M 65
ASSF Assisted 4 Living, Inc. $1.00 +0.00% $45.35M 63
SLHGP Skylight Health Group Inc. $12.00 -5.88% 61

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are JDHIF's Key Strengths?

  • Strong online platform with a diverse range of healthcare products and services.
  • Established brand presence through parent company JD.com.
  • Innovative solutions enhancing customer engagement and loyalty.

What Are JDHIF's Weaknesses?

  • Limited international presence compared to global competitors.
  • Dependence on the Chinese market for revenue generation.
  • No dividend yield may deter income-focused investors.

What Could Drive JDHIF Stock Higher?

  • Expansion of online pharmacy services projected to increase market share.
  • Strong demand for online healthcare services driving revenue growth.
  • Continuous innovation in health management solutions enhancing customer engagement.

What Are the Key Risks for JDHIF?

  • Regulatory changes impacting the healthcare industry in China.
  • Intense competition from established healthcare companies affecting market position.
  • Economic downturns influencing consumer spending on healthcare services.

What Are the Growth Opportunities for JDHIF?

  • Growth opportunity 1: The online pharmacy market in China is projected to reach $48 billion by 2025, presenting a significant growth opportunity for JD Health as it expands its online retail pharmacy network. The company's established infrastructure and brand recognition will enable it to capture a larger market share in this rapidly growing segment.
  • Growth opportunity 2: The demand for online healthcare services, including consultations and health management solutions, is expected to grow at a CAGR of 20% through 2027. JD Health's diverse service offerings position it to capitalize on this trend, enhancing customer engagement and loyalty.
  • Growth opportunity 3: The genetic testing market in China is anticipated to grow to $10 billion by 2026, driven by increasing consumer awareness and technological advancements. JD Health's investment in genetic testing services can leverage this growth, attracting health-conscious consumers seeking personalized healthcare solutions.
  • Growth opportunity 4: With the rise of health supplements and wellness products, JD Health can tap into the expanding market, projected to reach $25 billion by 2025. By enhancing its product range in this category, the company can cater to the growing consumer preference for preventive healthcare.
  • Growth opportunity 5: The increasing focus on medical aesthetics and beauty care services represents a lucrative market for JD Health. As consumer spending in this sector continues to rise, the company can expand its service offerings to capture a share of this growing demand.

What Opportunities Does JDHIF Have?

  • Growing demand for online healthcare services and products.
  • Expansion potential in the genetic testing and wellness markets.
  • Increasing consumer preference for convenient healthcare solutions.

What Threats Does JDHIF Face?

  • Regulatory changes affecting the healthcare industry in China.
  • Intense competition from established pharmaceutical and healthcare companies.
  • Market volatility impacting consumer spending on healthcare services.

What Are JDHIF's Competitive Advantages?

  • Strong brand recognition as a subsidiary of JD.com.
  • Comprehensive online platform offering diverse healthcare services.
  • Established infrastructure for efficient product distribution and service delivery.
  • Robust customer base with increasing demand for digital health solutions.
  • Innovative healthcare solutions that enhance customer engagement.

What Does JDHIF Do?

JD Health International Inc. was founded in 2018 and is headquartered in Beijing, China. As a subsidiary of JD Jiankang Limited, the company has positioned itself as a leader in the online healthcare space, capitalizing on the growing trend of digital health solutions in the People's Republic of China. JD Health operates a multifaceted online platform that provides a variety of pharmaceutical and healthcare products, including over-the-counter (OTC) drugs, prescription medications, medical devices, and health supplements. Additionally, the company offers a range of online healthcare services such as consultations, hospital referrals, health check-ups, genetic testing, and beauty care services. The platform also includes health management solutions and technical services, enhancing its value proposition to consumers. With a workforce of 3,564 employees, JD Health has rapidly grown its market presence, leveraging the robust infrastructure of its parent company, JD.com, to reach a wide customer base across China. The company's commitment to innovation and quality healthcare services positions it favorably within the competitive landscape of the healthcare industry.

What Products and Services Does JDHIF Offer?

  • Operate an online healthcare platform in China.
  • Provide a wide range of pharmaceutical products, including OTC and prescription drugs.
  • Offer medical devices and health supplements through direct selling and online retail.
  • Deliver online healthcare services, including consultations and health check-ups.
  • Facilitate hospital and doctor referrals for patients.
  • Provide genetic testing and beauty care services.
  • Offer health management and intelligent healthcare solutions.

How Does JDHIF Make Money?

  • Revenue generated through the sale of pharmaceutical and healthcare products.
  • Income from online healthcare services, including consultations and referrals.
  • Earnings from health management solutions and technical services.
  • Direct sales of health supplements and medical devices.
  • Advertising and promotional services related to healthcare offerings.

What Industry Does JDHIF Operate In?

The healthcare industry in China is experiencing significant growth, driven by increasing demand for digital health solutions and a rising aging population. The market is projected to expand as consumers increasingly seek convenient access to healthcare services. JD Health International Inc. is well-positioned within this landscape, competing with established firms such as Bayer AG (BAYRY) and Koninklijke Philips N.V. (RYLPF). As telemedicine and online healthcare services gain traction, JD Health's robust online platform and diverse service offerings enhance its competitive edge.

Who Are JDHIF's Key Customers?

  • Consumers seeking convenient access to healthcare products and services.
  • Patients looking for online consultations and referrals.
  • Health-conscious individuals interested in supplements and wellness products.
  • Individuals requiring medical check-ups and genetic testing.
  • Beauty care consumers seeking aesthetic services.
AI Confidence: 71% Updated: Jun 14, 2026

How JD Health International Inc. Is Valued

JD Health International Inc. carries a market capitalization of $18.66B, placing it in the large-cap category. Relative to its peer group, JDHIF's quantitative score of 51/100 is roughly in line with the peer average of 50/100.

Company Profile

JD Health International Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Cao Dong. JDHIF has traded publicly since 2020.

ROE 9%Key Financial Metrics

Return on equity for JD Health International Inc. stands at 9.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.6%, showing how much profit it generates from its asset base. JDHIF trades at a trailing price-to-earnings ratio of 16.89, below the Healthcare sector average of ~23x. Its free cash flow yield is 11.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

JD Health International Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.73 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project JD Health International Inc. revenue of about $88.91B for fiscal 2026, with EPS near $1.86. The estimate reflects 18 contributing analysts.

JDHIF Financials

Fundamental Snapshot

Revenue Growth (FY)
+23.0%
Net Income Growth (FY)
+25.8%
EPS Growth (FY)
+27.3%
Free Cash Flow Growth (FY)
+133.9%
P/E (TTM)
16.9
Return on Equity (TTM)
+9.1%
Current Ratio
2.7
EV/EBITDA (TTM)
15.1

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Strong online platform with a diverse range of healthcare products and services.
  • Established brand presence through parent company JD.com.
  • Innovative solutions enhancing customer engagement and loyalty.
  • Upcoming: Expansion of online pharmacy services projected to increase market share.

Bear Case

  • Limited international presence compared to global competitors.
  • Dependence on the Chinese market for revenue generation.
  • No dividend yield may deter income-focused investors.
  • Potential: Regulatory changes impacting the healthcare industry in China.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026

JDHIF Latest News

No recent news available for JDHIF.

JDHIF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JDHIF.

Price Targets

Wall Street price target analysis for JDHIF.

JDHIF MoonshotScore

51/100

What does this score mean?

The MoonshotScore rates JDHIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Cao Dong

CEO

Cao Dong has a robust background in the healthcare and technology sectors. He holds a degree in Business Administration and has extensive experience in managing large teams and operations within the healthcare industry. Prior to leading JD Health, he held various strategic roles in technology-driven healthcare companies, focusing on digital transformation and service innovation.

Track Record: Under Cao Dong's leadership, JD Health has expanded its online healthcare platform significantly, increasing its market share in the competitive landscape. He has been instrumental in driving the company's growth strategy, focusing on innovative healthcare solutions and enhancing customer engagement.

JDHIF OTC Market Information

The OTC Other tier includes companies that trade on the over-the-counter market but do not meet the requirements for higher tiers like NYSE or NASDAQ. This tier often includes smaller companies or those with less stringent reporting requirements, which can affect liquidity and transparency.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Liquidity can be lower in the OTC market, with potential challenges in executing large trades. The bid-ask spread may be wider compared to stocks listed on major exchanges, which can impact trading costs.
OTC Risk Factors:
  • Potential lack of liquidity, making it difficult to buy or sell shares quickly.
  • Less stringent regulatory oversight compared to companies listed on major exchanges.
  • Increased volatility due to lower trading volumes.
Due Diligence Checklist:
  • Review the company's financial statements for accuracy and transparency.
  • Assess the management team’s track record and experience.
  • Monitor industry trends and regulatory changes affecting the healthcare sector.
  • Evaluate the competitive landscape and market positioning.
  • Verify the company's compliance with OTC market regulations.
Legitimacy Signals:
  • Affiliation with JD.com, a well-established company in the e-commerce sector.
  • Transparency in financial reporting and disclosures.
  • A growing customer base and increasing market share in the healthcare sector.

JD Health International Inc. Healthcare Stock: Key Questions Answered

What does JD Health International Inc. do?

JD Health International Inc. operates a comprehensive online healthcare platform in China, providing a wide range of pharmaceutical products, including OTC and prescription drugs, as well as various healthcare services such as online consultations, hospital referrals, and health management solutions. The company aims to enhance access to healthcare through innovative digital solutions.

What are the main risks for JDHIF?

JD Health International Inc. faces several risks, including potential regulatory changes that could impact operations within the Chinese healthcare sector. Additionally, intense competition from established companies may affect market share and pricing strategies. Economic fluctuations could also influence consumer spending on healthcare services, posing further risks to revenue growth.

What revenue streams does JD Health International Inc. have in healthcare?

JD Health generates revenue through multiple streams, including the sale of pharmaceutical products, both OTC and prescription, as well as income from online healthcare services such as consultations and referrals. The company also earns from health management solutions and technical services, along with direct sales of health supplements and medical devices.

What are the key factors to evaluate for JDHIF?

JD Health International Inc. (JDHIF) holds an AI score of 51/100 (moderate). Not financial advice.

How frequently does JDHIF data refresh on this page?

JDHIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven JDHIF's recent stock price performance?

JD Health International Inc. (JDHIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong online platform with a diverse range of healthcare products and services. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider JDHIF overvalued or undervalued right now?

Valuing JD Health International Inc. (JDHIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying JDHIF?

Before investing in JD Health International Inc. (JDHIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is subject to change; verify with the latest reports.
Data Sources

Popular Stocks